← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Irisys, Inc.
San Diego, CA
$7,923,181
Total funding
4
Grants
Funding over time
peak $1.4M · FY2010–24$2M$1.5M$1M$500K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$7,923,181 · 4
By mechanism
N02$5,658,330 · 2
N01$2,264,851 · 2
Investigators at Irisys, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Not enough data
Largest grants
NEXT DTP-22-013, PRODUCTION OF TAK-243 INJECTABLE FOR CLINICAL USE$639,151
N02 · FY2022 · CA
SOCIETAL IS A SMALL BUSINESS CONCERN FOR DOSAGE FORM DEVELOPMENT, MANUFACTURE, AND STABILITY STUDIES OF NCGC72$565,585
N01 · FY2024 · DA
PRODUCTION OF VARIOUS STRENGTH OF INJECTABLE LMP744 FOR CLINICAL USE; POP: 02/14/2020 - 02/13/2021$512,500
N02 · FY2020 · CA
PRODUCTION OF AMMONIUM TETRATHIOMOLIBDATE (ATTM) CAPSULES FOR USE IN CLINICAL TRIALS$413,130
N01 · FY2022 · CA
DEVELOPMENT & MANUFACTURE OF ORAL & TOPICAL DOSAGE FORMS - NOVOBIOCIN CAPSULE PRODUCTION BASE (TASK 1) 12 MONTHS & OPTION 1 (TASK 2) A CGMP BATCH SHEL$412,500
N02 · FY2021 · CA
TAS::75 0849::TAS DEVELOPMENT AND MANUFACTURE OF ORAL AND TOOPICAL DOSAGE FORMS$326,727
N02 · FY2010 · CA
TAS::75 0849::TAS DEVELOPMENT AND MANUFACTURE OF ORAL AND TOOPICAL DOSAGE FORMS$309,851
N01 · FY2014 · CA
TAS::75 0849::TAS DEVELOPMENT AND MANUFACTURE OF ORAL AND TOOPICAL DOSAGE FORMS$283,206
N02 · FY2013 · CA
PRODUCTION OF A CGMP BATCH OF TRIAPINE INJECTION$249,951
N02 · FY2021 · CA
Z-Endoxifen HCl Capsules$239,627
N02 · FY2017 · CA
Production of LMP-744 Injection for Clinical Use$196,244
N02 · FY2019 · CA
NEXT DTP-22-018, GMP PRODUCTION OF 40 MG Z-ENDOXIFEN (NSC 774768) CAPSULES$189,535
N02 · FY2022 · CA
SOCIETAL IS A SMALL BUSINESS CONCERN FOR DOSAGE FORM DEVELOPMENT, MANUFACTURE, AND STABILITY STUDIES OF NCGC72$182,902
N01 · FY2023 · DA
THIS TASK ORDER (TO) IS TO PROVIDE DOSAGE FORM DEVELOPMENT, MANUFACTURE AND STABILITY STUDIES OF ORC-13661 FOR PHASE II CLINICAL TRIAL$180,000
N01 · FY2024 · DA
IGF::OT::IGF$179,379
N02 · FY2017 · CA
Indenos (LMP744, NSC 706744) for Injection$178,467
N02 · FY2018 · CA
AZA-TDC CAPSULES FOR USE IN CLINICAL TRIAL$177,135
N01 · FY2022 · CA
Production of 50 mL fill of 1 mg/mL injectable LMP-744$176,862
N02 · FY2019 · CA
IGF::OT::IGF SPECIAL STUDIES/ANALYSIS- CHEMICAL/BIOLOGICAL$156,438
N02 · FY2016 · CA
TAS::75 0849::TAS DEVELOPMENT AND MANUFACTURE OF ORAL AND TOOPICAL DOSAGE FORMS$144,980
N02 · FY2015 · CA